Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPassage Bio Inc

Passage Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.46 USD -0.05 ( 1.42%)
Last update at 2026-11-05T21:00:00Z
VOLUME
28139
Market Cap
73.35M

Momentum Score

…

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.39
Low
3.56
High
52 Week Price Range
0.57
Low
1.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.51
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.24
ROE
-61.36%
Net Debt
4.58M
ROCE
-103.12%
Diluted EPS TTM
-1.58

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -136.12M -185.39M -112.23M -45.63M -12.77M
Net income -136.86M -191.50M -111.76M -54.58M -12.77M
Selling general administrative 49.34M 60.06M 30.11M 6.95M 0.93M
Reconciled depreciation 3.68M 1.54M 0.80M 0.13M 0.00M
Ebit -138.39M -185.73M -112.90M -37.19M -8.12M
Ebitda -132.39M -169.73M -110.90M -26.91M -7.42M
Depreciation and amortization 6.00M 16.00M 2.00M 10.28M 0.70M
Non operating income net other 1.72M -0.06M 0.67M - -
Operating income -138.39M -185.73M -112.90M -37.19M -13.47M
Other operating expenses 135.39M 177.73M 111.90M 36.69M 10.10M
Interest expense 2.27M 0.34M 0.67M 8.45M 0.70M
Interest income 2.27M 0.34M 0.67M 0.70M 0.00M
Net interest income 2.27M 0.34M 0.67M 0.70M 0.00M
Non recurring 3.00M 8.00M 1.00M - -
Income tax expense 0.73M 6.11M -0.47M 8.95M -0.70M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 135.39M 177.73M 111.90M 36.69M 10.10M
Total other income expense net 2.27M 0.34M 0.67M -8.45M -2.67M
Net income from continuing ops -136.68M -185.79M -112.23M -45.63M -12.77M
Net income applicable to common shares -136.12M -185.39M -112.23M -45.63M -12.77M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 150.54M 243.55M 355.08M 328.01M 178.61M
Other current assets 3.67M 0.93M 1.73M 12.37M 6.90M
Total liab 39.26M 42.18M 36.42M 23.29M 4.26M
Total stockholder equity 111.28M 201.37M 318.66M 304.71M 174.35M
Deferred long term liab - - - 0.20M 1.70M
Other current liab 11.67M 11.01M 20.05M 15.91M 3.05M
Common stock 0.01M 0.01M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.00M 0.00M
Retained earnings -594.47M -492.41M -356.28M -170.90M -58.66M
Other liab - - 6.92M 2.12M 0.58M
Other assets 0.00M 4.27M 6.20M 2.79M 11.75M
Cash 21.71M 34.60M 128.97M 135.00M 158.87M
Total current liabilities 16.34M 18.35M 29.50M 21.18M 3.68M
Net debt 4.58M -7.49M -128.97M -135.00M -158.87M
Short term debt 3.37M 3.27M - - -
Short long term debt total 26.29M 27.11M - - -
Other stockholder equity 705.79M 694.73M 675.35M 147.61M 233.01M
Property plant equipment - 22.52M 23.81M 2.79M 1.09M
Total current assets 117.96M 197.04M 325.07M 317.18M 165.78M
Net tangible assets - 201.37M 318.66M 304.71M -56.25M
Short term investments 92.58M 155.01M 186.81M 169.81M -
Net receivables - 4.27M 6.20M 8.03M -
Accounts payable 1.30M 4.07M 9.45M 5.26M 0.63M
Accumulated other comprehensive income -0.04M -0.97M -0.41M -0.01M -0.13M
Common stock total equity - 0.01M 0.01M 0.00M 0.00M
Retained earnings total equity - -492.41M -356.28M -170.90M -
Non currrent assets other 0.43M 4.27M 6.20M 5.23M 11.75M
Non current assets total 32.59M 46.51M 30.01M 8.03M 12.84M
Capital lease obligations 26.29M 27.11M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 30.47M -20.17M -170.46M -170.46M -2.54M
Change to liabilities -12.75M 6.18M 16.79M 0.40M 0.21M
Total cashflows from investing activities 25.20M -45.81M -172.11M -1.69M -2.54M
Total cash from financing activities -1.35M 166.66M 228.75M 175.60M 45.97M
Change to operating activities -3.08M 9.22M 9.85M -6.34M -8.74M
Net income -136.12M -185.39M -112.23M -45.63M -12.77M
Change in cash -94.36M -6.04M -23.87M 134.01M 24.86M
Begin period cash flow 128.97M 135.00M 158.87M 24.86M 0.00M
End period cash flow 34.60M 128.97M 135.00M 158.87M 24.86M
Total cash from operating activities -118.21M -126.88M -80.52M -39.90M -18.57M
Issuance of capital stock 0.00M 165.81M 228.26M 176.19M 45.97M
Depreciation 3.68M 1.54M 0.80M 0.13M 0.13M
Other cashflows from investing activities -3.00M -8.00M -0.50M - -
Change to account receivables - - - 0.40M 0.21M
Sale purchase of stock 0.30M 0.89M 0.28M - -
Other cashflows from financing activities -1.79M -0.04M 0.21M 175.60M 45.97M
Change to netincome 18.95M 32.69M 14.58M 11.55M 2.73M
Capital expenditures 5.27M 25.64M 1.65M 1.69M 2.54M
Cash flows other operating 7.26M 15.31M -1.09M - -
Cash and cash equivalents changes -94.36M -6.04M -23.87M - -
Change in working capital -8.49M 11.42M 14.44M -5.94M -8.52M
Stock based compensation 18.95M 32.69M 14.58M 1.45M -
Other non cash items 3.77M 10.07M 1.26M 0.95M 2.73M
Free cash flow -123.48M -152.52M -82.17M -41.59M -21.11M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PASG
Passage Bio Inc		 -0.05
1.42%		 3.46 - - - 0.75 0.05
NVO
Novo Nordisk A/S		 -1.88
4.46%		 40.30 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -6.54
1.19%		 542.50 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -27.77
2.98%		 902.90 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

One Commerce Square, Philadelphia, PA, United States, 19103

267 866 0311

https://www.passagebio.com

58

Name Title Year Born
Dr. William Chou M.D. CEO & Director NA
Dr. James M. Wilson M.D., Ph.D. Co-Founder & Chief Scientific Advisor 1955
Ms. Simona King CFO & Corp. Sec. 1972
Mr. Alexandros Fotopoulos MBA, MSc Chief Technical Officer 1969
Mr. Stuart M. Henderson VP of Corp. Devel. & Investor Relations NA
Mr. Edgar B. Cale Esq., J.D. Gen. Counsel & Company Sec. 1964
Gregory Fuest VP of Global Commercial Strategy & Marketing NA
Dr. Mark Forman M.D., Ph.D. Chief Medical Officer 1964
Desiree Luthman D.D.S. Sr. VP of Global Regulatory Affairs NA
David Weinstein M.D. Sr. VP of Clinical Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DHT-U
CAD 13.53
+16.44%
LIF
CAD 22.04
+8.62%
TOI
CAD 103.80
+7.09%
CRON
CAD 5.26
+6.69%
CIA
CAD 2.04
+6.25%
ITH
CAD 1.61
-34.02%
IFOS
CAD 1.65
-22.90%
TNZ
CAD 49.70
-19.58%
KEEL
CAD 2.36
-19.45%
GIL
CAD 49.36
-18.33%

Equity Sectors*

  • Basic Materials

    -2.18%

  • Communication Services

    +0.95%

  • Consumer Cyclical

    -2.25%

  • Consumer Defensive

    -0.68%

  • Energy

    -2.93%

  • Financial Services

    -2.26%

  • Healthcare

    -0.46%

  • Industrials

    -3.70%

  • Real Estate

    -0.06%

  • Technology

    -3.32%

  • Utilities

    -0.50%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…